Neuralink Rival Jieti Medical Advances China's First Implantable Brain-Computer Interface with Full Clinical and Commercial Roadmap

This time, the National Healthcare Security Administration has comprehensively reviewed and standardized the pricing projects for neurological medical services from the perspective of facilitating the transformation of innovative technologies into clinical treatments.Set up projects for cutting-edge technologies such as brain-computer interfaces, fully support the value realization of high-level medical technology, and after localities align and implement the project initiation guidelines, the charging for brain-computer interface medical services will be regulated.

Brain-Computer Interface, which is to establish a direct connection pathway between the brain and external devices. When the brain engages in mental activities, it generates brain waves. Brain-computer interfaces directly read the brain's intentions by identifying the characteristics of these brain waves, converting them into computer commands to achieve interconnected communication between humans and machines or the external environment.Creating solutions to enable the paralyzed to walk and the speech-impaired to communicate"Speaking," allowing the blind to "regain sight," and other miracles.

On January 30, 2024, Elon Musk announced that his brain-computer interface company Neuralink had completed the first human brain device implant surgery. Subsequently, the first human patient with the brain chip successfully controlled a computer mouse using their thoughts. This marks an important milestone for brain-computer interface technology transitioning from fundamental research to the market.

The enterprise StairMed, located in the Xingbei FT1 park, has chosen the highly technically challenging and application-ceilinged invasive brain-computer interface technology path like Neuralink, and developed the first high-throughput implantable brain-computer interface system in China that meets medical device standards. This is to assist paralyzed patients in completing complex brain-controlled tasks.China's First Invasive Brain-Computer Interface Product to Complete Registrational Type Inspection。

StairMed successfully made it to the MIIT's 2023 Future Industry Innovation Task "Challenge Leader" project list with this project,The only implantable brain-computer interface enterprise rated in Shanghai, and received support from the 2024 Shanghai Annual "Science and Technology Innovation Action Plan" Brain-Computer Interface Project.

In February this year, StairMed announced the completionRMB 350 million Series B financingThis round of funding will be used to accelerate product clinical trials, the development of next-generation technologies, and the construction of a medical-grade MEMS production base, providing strong support for the commercial implementation of brain-computer interface technology.

This financing represents the largest single funding round in the history of China's implantable brain-computer interface industry. Prior to this, StairMed had secured Series A financing worth several hundred million yuan as well as tens of millions in angel round funding.

Currently, StairMed has collaborated with several top-tier hospitals in China.Has carried out cumulative over50 Cases of Investigator-Initiated Trials (IIT) Related to Brain-Computer Interface, achieved remarkable clinical results, and built the world's largest flexible electrode human single-cell dataset. StairMed plans to launch in 2025.China's First Invasive Brain-Computer Interface Long-Term Implant Prospective Clinical Trial (FIM）, and to further advance large-scale clinical trials by 2026, paving the way for product registration and market entry.

StairMed has achieved a revolutionary breakthrough in neural electrode technology: adopting an ultra-flexible electrode design,The size is only as thick as a hair.1/100 (1/5 of Neuralink), hundreds of times softer than Neuralink，Making it difficult for brain tissue to "sense" the "foreign invasion" of electrodes, Shanghai StairMed Technology Co., Ltd. has developed the first neural electrode interface that does not form immune scars, ensuring long-term stable recording of neural activity. By introducing semiconductor micro-nano processing technology, the company has solved the scalability production challenges of medical-grade brain-computer interface electrodes.

In terms of implant design and surgical procedures, StairMed's implants are only half the size of Neuralink's. The implant surgery requires only a 3-5 millimeter micro-hole in the skull and can be completed using mature minimally invasive neurosurgical puncture techniques, significantly reducing surgical trauma and risks.With this innovative design, StairMed's product becomes the smallest-sized and least invasive implantable brain-computer interface system currently available.。

In terms of mass production capability, to ensure product reliability, StairMed has built a 2,000-square-meter production plant that meets international GMP standards for production management and quality requirements. This includes a 300-square-meter Class 10,000 cleanroom and an independent quality inspection laboratory. The company plans toThe first medical-grade brain-computer interface MEMS production base in China to be completed in 2025.Achieve a full-chain closed loop of "R&D - Production - Quality Inspection".

As a pioneer in China's implantable brain-computer interface field, StairMed has always been in sync with national strategies and deeply integrated into Shanghai's grand blueprint to build a global highland for the brain-computer interface industry. Guided by the "Shanghai Brain-Computer Interface Future Industry Cultivation Action Plan (2025-2030)," driven by innovation, and oriented toward clinical needs, the company is accelerating the advancement of technology transformation and industrial implementation.

According to the plan, StairMed will launch the first-in-human (FIM) prospective clinical trial for the long-term implantation of invasive brain-computer interface in China in 2025, and further expand the trial scale in 2026, making an all-out push for product registration and market launch. This milestone not only marks a key breakthrough in the clinical application of brain-computer interface technology in China, but also brings hope to patients with aphasia and paralysis to regain their language and motor functions.

In the Waigaoqiao Bonded Area, within the StarBay Free Trade No.1 Park, stands a small building that combines R&D and production – the home of StairMed. From the research and development of brain-computer interfaces to their clinical applications, StarBay·Free Trade No.1 provides the industry with a complete upstream and downstream industrial chain, enabling companies to efficiently share resources and technologies, and promoting the research and development and production of innovative drugs.

"Becoming the stepping stone of human progress" is the corporate mission of StairMed. With technological innovation and industrial practice, StairMed is redefining the boundaries between healthcare and technology. As capital and resources continue to pour in, this revolution in human-machine interaction, which concerns the future, has already hit the fast-forward button.